BNC105

BNC105 is a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.IC50 value: Target:BNC105 exhibited excellent potency against a panel of different cancer cell lines with IC50 <1 nM for DU145, Calu-6, MDA-MB-231 etc. The selectivity observed for BNC105 against activated over quiescent HUVECs was also observed in human aortic arterial endothelial cells (HAAECs). BNC105 also exhibited good potency toward the cisplatin resistant cell line A2780cis.

Signaling Pathways >> Cell Cycle/DNA Damage >> Microtubule/Tubulin

Signaling Pathways >> Cytoskeleton >> Microtubule/Tubulin

Research Areas >> Cancer

[1]. Flynn BL, et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem. 2011 Sep 8;54(17):6014-27.

[2]. Kremmidiotis G, et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther. 2010 Jun;9(6):1562-73.

[3]. Inglis DJ, et al. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer. Cancer Biol Ther. 2014;15(11):1552-60.

Nocodazole | Monomethyl auristatin E | VcMMAE | Mertansine | Eribulin mesylate | Epothilone D | Vinorelbine (ditartrate) | epothilone B | McMMAF | MMAF (Hydrochloride) | Ixabepilone | Taltobulin | Estramustine phosphate sodium | Ansamitocin P-3 | Combretastatin A4 disodium phosphate